RENOVARO INC (RENB)

US29350E1047 - Common Stock

0.7564  +0.15 (+23.94%)

After market: 0.769 +0.01 (+1.67%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RENB. RENB was compared to 571 industry peers in the Biotechnology industry. While RENB seems to be doing ok healthwise, there are quite some concerns on its profitability. RENB has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year RENB has reported negative net income.
RENB had a negative operating cash flow in the past year.
RENB had negative earnings in each of the past 5 years.
RENB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RENB has a worse Return On Assets (-94.96%) than 73.72% of its industry peers.
RENB has a Return On Equity of -117.94%. This is comparable to the rest of the industry: RENB outperforms 42.33% of its industry peers.
Industry RankSector Rank
ROA -94.96%
ROE -117.94%
ROIC N/A
ROA(3y)-72.08%
ROA(5y)-46.53%
ROE(3y)-85.62%
ROE(5y)-54.83%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RENB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

The number of shares outstanding for RENB has been increased compared to 1 year ago.
RENB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RENB has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.62, we must say that RENB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.62, RENB is in line with its industry, outperforming 50.26% of the companies in the same industry.
RENB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.62
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.08 indicates that RENB may have some problems paying its short term obligations.
The Current ratio of RENB (0.08) is worse than 98.41% of its industry peers.
A Quick Ratio of 0.08 indicates that RENB may have some problems paying its short term obligations.
The Quick ratio of RENB (0.08) is worse than 98.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08

0

3. Growth

3.1 Past

RENB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.47%.
EPS 1Y (TTM)-33.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

RENB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for RENB!.
Industry RankSector Rank
Dividend Yield N/A

RENOVARO INC

NASDAQ:RENB (11/29/2024, 4:45:57 PM)

After market: 0.769 +0.01 (+1.67%)

0.7564

+0.15 (+23.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap120.06M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.96%
ROE -117.94%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-33.47%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y